IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023
Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.